Skip to content
Screener

BridgeBio Pharma BBIO Current Debt

Current Debt at other companies

Pfizer logo
PfizerPFE
$3.86B+3.0%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$658.2M—
Royalty Pharma logo
Royalty PharmaRPRX
$380M-62.0%

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K—
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$16.06B+87.5%
Enterprise value$18.44B+136%
P/S27.7×-8.6×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%—

Returns & leverage

See full
Return on equity-216.8%—
Debt / equity2×—
Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths.

The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:31 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001743881-26-000019
(in thousands)
Remainder of 2026$$2,517$$5,031$$8,409$$6,875$$22,832
Year ending December 31:
20274,74410,06316,819556,875588,501
20284,74410,06316,819—31,626
20294,74410,063755,909—770,716
20304,74410,063——14,807
20314,744580,031——584,775

Item 1. Financial Statements (Unaudited)

FAQ

What is BridgeBio Pharma's current debt?
BridgeBio Pharma (BBIO) reported current debt of $588.5M in Q1 2026.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.

Ask your AI about BridgeBio Pharma's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude